A61P 19/06
Antigout agents
Official title: Antigout agents, e.g. antihyperuricemic or uricosuric agents
A61P19/06 (Antigout agents) appears on 2,511 US grants and 3,929 published applications in this corpus.
Search patents in A61P- Granted patents
- 2,511
- Published applications
- 3,929
- Assignees
- 1,181
- Inventors
- 7,212
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 5 | 0 |
| 1977 | 0 | 0 |
| 1978 | 1 | 0 |
| 1979 | 3 | 0 |
| 1980 | 4 | 0 |
| 1981 | 4 | 0 |
| 1982 | 4 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 2 | 0 |
| 1986 | 5 | 0 |
| 1987 | 6 | 0 |
| 1988 | 2 | 0 |
| 1989 | 7 | 0 |
| 1990 | 2 | 0 |
| 1991 | 7 | 0 |
| 1992 | 3 | 0 |
| 1993 | 7 | 0 |
| 1994 | 4 | 0 |
| 1995 | 4 | 0 |
| 1996 | 8 | 0 |
| 1997 | 4 | 0 |
| 1998 | 11 | 0 |
| 1999 | 16 | 0 |
| 2000 | 17 | 0 |
| 2001 | 29 | 8 |
| 2002 | 35 | 51 |
| 2003 | 46 | 108 |
| 2004 | 25 | 185 |
| 2005 | 53 | 187 |
| 2006 | 77 | 192 |
| 2007 | 84 | 190 |
| 2008 | 108 | 227 |
| 2009 | 104 | 271 |
| 2010 | 167 | 328 |
| 2011 | 158 | 250 |
| 2012 | 183 | 243 |
| 2013 | 189 | 185 |
| 2014 | 176 | 201 |
| 2015 | 165 | 194 |
| 2016 | 115 | 142 |
| 2017 | 127 | 185 |
| 2018 | 116 | 148 |
| 2019 | 106 | 114 |
| 2020 | 82 | 112 |
| 2021 | 69 | 96 |
| 2022 | 49 | 71 |
| 2023 | 32 | 75 |
| 2024 | 33 | 64 |
| 2025 | 35 | 59 |
| 2026 | 21 | 43 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Gout flare prevention methods using IL-1β blockers25 Aug 2026US 12,715,915 B2
- Therapeutic engineered microbial cell system and methods for treating hyperuricemia and gout11 Aug 2026US 12,703,849 B2Unlocked Labs
- Substituted pyrazolo[3,4-b]pyridines as ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) modulators2 Jun 2026US 12,643,910 B2Sanford Burnham Prebys Medical Discovery Institute
- Fc region variant2 Jun 2026US 12,643,937 B2Chugai Seiyaku Kabushiki Kaisha
- Use of a vegetal extract from Salvia haenkei as an active agent in the treatment of a musculoskeletal disorder26 May 2026US 12,636,336 B2Ibsa Institut Biochimique SA
- Uric acid transporter agonist compound, pharmaceutical composition, and preparation method therefor and use thereof8 Oct 2026US 2026/0308136 A1Hangzhou E & J Biopharmaceutical Technology Co., Ltd.
- Compounds and dosage regimen for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases10 Sep 2026US 2026/0263399 A1Immunic AG
- Use of composition containing candesartan or azilsartan10 Sep 2026US 2026/0263425 A1Gachon University of Industry-Academic Cooperation Foundation
- Formulations of (+)-2-[1-(3-ethoxy-4- methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione27 Aug 2026US 2026/0248727 A1Amgen Inc.
- Composition and Method for Synthesizing Pegylated Uricase-Drug Conjugates to Mitigate Anti-Drug Antibody and Their Therapeutic Use27 Aug 2026US 2026/0248931 A1Oncoc4, Inc.
Most cited
By later US patents
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions930US 6,248,363 B1Lipocine Inc. · 2001
- Solid carriers for improved delivery of active ingredients in pharmaceutical compositions684US 6,923,988 B2Lipocine Inc. · 2005
- Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions616US 6,569,463 B2Lipocine Inc. · 2003
- Human antibodies that bind human TNF.alpha.451US 6,090,382 ABASF SE · 2000
- Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents342US 6,309,663 B1Lipocine Inc. · 2001